
USD
+$0.00
(+0.00%
)At Close (As of Dec 15, 2025)
$582.39M
Market Cap
19.89
P/E Ratio
0.18
EPS
$5.13
52 Week High
$0.52
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $104M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2M |
| Capital Expenditures | $142K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$142K |
| Cashflow From Financing | -$107M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $880K |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Ironwood Pharmaceuticals, Inc. is a leading biotechnology company based in Boston, Massachusetts, dedicated to developing and commercializing innovative therapies for gastrointestinal disorders. The firm is best known for its flagship product, Linzess (linaclotide), which addresses critical unmet needs in the gastroenterological field, bolstered by a promising pipeline of additional therapies. Ironwood's strong focus on research and development, coupled with strategic partnerships, not only enhances its competitive positioning but also signals potential for sustainable growth and long-term value creation for institutional investors while advancing patient care.